DFX Intelligence
Venture Capital Intelligence
The names on this page are hidden. Create a free account to reveal 5 records a month, or get Venture Capital Intelligence at $199 a month for every name. Every figure, date and source on this page is public either way.
Firms / S•••• E••••• M••••••••• L••
S•••• E••••• M••••••••• L••
venture manager, reported GAV $31.8M across 2 vehicles
Importance
22
moderate
Active deployment
55
elevated
Emerging
71
high
Completeness
69
high
Freshness
97
high
Research priority
35
elevated
Identity and regulatory footprint
- Headquarters
- Wilmette, ILadviserinfo.sec.gov
- Office address
- 1136 CHESTNUT AVE, Wilmette, IL, 60091adviserinfo.sec.gov
- Business phone
- 224-223-5242adviserinfo.sec.gov
- Website
- s•••••••••.com
- SEC adviser type
- exempt reporting adviseradviserinfo.sec.gov
- SEC exemption claimed
- venture capital fund adviseradviserinfo.sec.govItem 2.B(1): advises solely venture capital funds
- Latest Form ADV
- Mar 26, 2026
- Private funds reported
- 4 (1 venture capital funds)adviserinfo.sec.gov
- Private fund gross assets
- $55.0Madviserinfo.sec.govreported GAV of the funds, the adviser's own number; not fund size, not dry powder
- business phone
- 224-223-5242adviserinfo.sec.govpublished by the subject
Stated thesis versus observed behaviour
18 observed deals
Stated (the firm’s website)
- Sectors
- healthcare, medtech
- Stages
- growth
- Geography
- boston
- Check size
- not stated; DFX does not estimate checks from round sizes
- Self-described
- venture capital
Observed (from deals on record)
Stage at participation: no observed deals yet
Stage at first entry: no observed deals yet
Sectors
unknown 89%Other Health Care 11%
lead rate n/afollow-on rate n/anew logos, 12 months 18
Funds and vehicles
2 reported
| Vehicle | Type | Vintage | Lifecycle | Reported GAV | Owners | Form D sold | Latest Form D |
|---|---|---|---|---|---|---|---|
| S•••• E••••• F••• I• L• | Fund | 2023 form d first sale | Active deployment | $29.3M May 24, 2024 | 49 | $33.8M | Dec 10, 2024 |
| S•••• E••••• O••••••••• F••• S••• L•• | SPV or co-invest vehicle · ADV: Other Private Fund | 2023 form d first sale | Active deployment | $2.5M May 24, 2024 | 3 | $2.5M of $2.5M | May 25, 2023 |
GAV is the gross asset value the adviser reported on Form ADV for the vehicle, never the fund’s committed size and never dry powder. Form D sold is the amount sold as of the latest filing, never a final close.
Investment team
20 current, 0 departed
A•••• C•••••
Founder or executiveCEO Apax Partners Portfolio Company
D••••• H••••••
Founder or executiveFounder of Shockwave M••••••
D•••• G•••••
Founder or executiveFormer Intl. President of St. Jude M••••••
D•• A•••• K•••••
Founder or executiveFounder of C•••••••• M••••••
D•• T•• D•••
Founder or executiveChairman of ASPN
F••• K•••••••
Founder or executiveChairman and CEO Imperative Care
L•••••• I••••••••• C•••••••••
Founder or executiveFounder of most promising next gen left atrial appendage device – C•••••••• M••••••
R•••• A•••••••
Founder or executiveFounder of BioQuest
S•••• W•••
Founder or executiveCEO Cardiovascular Systems, Inc
R•••••• R••••
General partnerCo-Founder & Partner
E••• L••••
Managing partnerManaging Partner Shoni Health Ventures
E••• N•••••
Managing partnerManaging Partner · since Mar 1, 2024
E••• N•••••
Managing partnerCo-Founder & Managing Partner
K•••• A•••••
Operating partnerCo-Founder & Operating Partner
K•••• A•••••
Operating partnerOperating Partner · since Mar 1, 2024
R•••••• R••••
Platform and operationsInvestment Partner; Chief Compliance Officer · since Mar 1, 2024
C•••• R••••••
PrincipalClinical Principal
D•• V•••• R••••
PrincipalDirector of Cardiac Arrhythmia, Mt. Sinai
A••••• M•••••••
Venture partnerVenture Partner
O•••••• D•••••••
Venture partnerVenture Partner
Investments on record
18 edges, 18 companies, 0 partner-attributed
“This investor” is the amount disclosed for this investor alone; it is unknown unless a source said it. The round size is the whole round.
Co-investors
5 relationships from shared deals, counted for the whole firm
Limited partners
0 disclosed
No LP commitment on record. An LP edge needs a public disclosure with a quote: a pension report (see Limited partners for the plans read), a fund announcement naming the LP, or a Form ADV owner. The fund page carries the LP’s reported performance.
Timeline
15 dated events
- Sep 16, 2026V••••• M••••••: acquired by Stryker on or before 2026-09-16 (no date published), per S•••• E••••• M••••••••• L••'s portfolio page
- Sep 16, 2026T•• M••••••: acquired by BD on or before 2026-09-16 (no date published), per S•••• E••••• M••••••••• L••'s portfolio page
- Sep 16, 2026T•••••: acquired by Abbott on or before 2026-09-16 (no date published), per S•••• E••••• M••••••••• L••'s portfolio page
- Sep 16, 2026T•••••• H•••••••: acquired by Abbott on or before 2026-09-16 (no date published), per S•••• E••••• M••••••••• L••'s portfolio page
- Sep 16, 2026A•••••: acquired by Medtronic on or before 2026-09-16 (no date published), per S•••• E••••• M••••••••• L••'s portfolio page
- Sep 16, 2026R••••••• M••••••: acquired by Boston Scientific on or before 2026-09-16 (no date published), per S•••• E••••• M••••••••• L••'s portfolio page
- Sep 16, 2026N••••••••: went public by IPO on or before 2026-09-16 (no date published), per S•••• E••••• M••••••••• L••'s portfolio page
- Sep 16, 2026P••••••: acquired by Boston Scientific on or before 2026-09-16 (no date published), per S•••• E••••• M••••••••• L••'s portfolio page
- Sep 16, 2026C•••••••• M••••••• I•••: acquired by W.L. Gore on or before 2026-09-16 (no date published), per S•••• E••••• M••••••••• L••'s portfolio page
- Sep 16, 2026S•••• M••••••: acquired by Boston Scientific on or before 2026-09-16 (no date published), per S•••• E••••• M••••••••• L••'s portfolio page
- Sep 16, 2026B••••••••• M••••••: acquired by Boston Scientific on or before 2026-09-16 (no date published), per S•••• E••••• M••••••••• L••'s portfolio page
- Sep 16, 2026R•••••••••: acquired by Zoll on or before 2026-09-16 (no date published), per S•••• E••••• M••••••••• L••'s portfolio page
- May 24, 2024S•••• E••••• O••••••••• F••• S••• L•• first reported on Form ADV by S•••• E••••• M••••••••• L•• (Other Private Fund), GAV $2,500,000Fund first reported on Form ADVFundsFactS•••• E••••• O••••••••• F••• S••• L••SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- May 24, 2024S•••• E••••• F••• I• L• first reported on Form ADV by S•••• E••••• M••••••••• L•• (Venture Capital Fund), GAV $29,340,000Fund first reported on Form ADVFundsFactS•••• E••••• F••• I• L•SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- May 24, 2024S•••• E••••• M••••••••• L•• first filed Form ADV (ERA, venture capital fund adviser exemption)First SEC adviser filingOrganizationFactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Classification history
- Sep 12, 2026Micro VC (confirmed, 95%, cls-1)venture manager, reported GAV $31.8M across 2 vehicles
Evidence
37 observations from 3 sources